Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

23.19
+0.38001.67%
Volume:276.10K
Turnover:6.43M
Market Cap:1.53B
PE:-7.46
High:23.60
Open:22.88
Low:22.51
Close:22.81
52wk High:30.99
52wk Low:10.30
Shares:66.17M
Float Shares:36.76M
Volume Ratio:0.55
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1097
EPS(LYR):-2.5230
ROE:-41.01%
ROA:-26.14%
PB:3.27
PE(LYR):-9.19

Loading ...

Bicara Therapeutics President, COO and Interim CEO Ryan Cohlhepp Disposes of Common Shares Worth $400,049.15

Reuters
·
Sep 11

Bicara Therapeutics: Buy Rating Reiterated on FICERA’s Survival Benefit in Difficult HNSCC Segment, Price Target Maintained at $30

TIPRANKS
·
Sep 08

Bicara Therapeutics Issues Inducement Stock Options for 380,575 Shares at $23.42 Each

Reuters
·
Sep 03

Bicara Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 03

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 03

Bicara Therapeutics Secures Boston Headquarters Through Sublease

TIPRANKS
·
Aug 26

How Bicara’s Leadership Overhaul and CEO Succession Plan Could Shape Bicara Therapeutics (BCAX) Investors

Simply Wall St.
·
Aug 24

Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf Filing - Has The Bull Case Changed?

Simply Wall St.
·
Aug 16

Bicara Therapeutics CFO Jennifer Larson Files Initial Beneficial Ownership Statement

Reuters
·
Aug 15

Bicara Awards CFO Jennifer Larson Stock Option for 285,000 Shares at $24.63 Each

Reuters
·
Aug 14

Bicara Therapeutics Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 14

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 14

Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

TIPRANKS
·
Aug 13

Mizuho Securities Reaffirms Their Hold Rating on Bicara Therapeutics Inc. (BCAX)

TIPRANKS
·
Aug 13

Bicara Therapeutics CFO Ivan Hyep Disposes of $349,591 in Common Shares

Reuters
·
Aug 13

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Benzinga Earnings
·
Aug 12

Bicara Therapeutics is Maintained at Buy by BTIG

Dow Jones
·
Aug 12

U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage

Reuters
·
Aug 12

Bicara Therapeutics Inc : Btig Raises Target Price to $39 from $28

THOMSON REUTERS
·
Aug 12

Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says

MT Newswires Live
·
Aug 12